About AnHeart Therapeutics

AnHeart Therapeutics is developing precision oncology therapeutics, including Taletrectinib for ROS1-positive non-small cell lung cancer and Safusidenib for IDH1-mutant gliomas and cholangiocarcinoma, both currently in Phase 2 clinical trials. The company targets specific genetic mutations in tumors to improve treatment efficacy and patient outcomes in cancer care.

```xml <problem> Many cancers are driven by specific genetic mutations, but traditional chemotherapy and radiation treatments lack the precision to target these mutations, leading to off-target effects and limited efficacy. This results in suboptimal patient outcomes and a need for therapies that selectively inhibit the growth of tumor cells harboring specific mutations. </problem> <solution> AnHeart Therapeutics develops precision oncology therapeutics designed to target specific genetic mutations found in tumors. Their lead compounds, Taletrectinib and Safusidenib, are designed to selectively inhibit ROS1 and IDH1 mutations, respectively. By targeting these specific mutations, the company aims to improve treatment efficacy and patient outcomes while minimizing off-target effects. Both Taletrectinib and Safusidenib are currently in Phase 2 clinical trials for various cancers. </solution> <features> - Taletrectinib: A ROS1 inhibitor in Phase 2 clinical trials for ROS1-positive non-small cell lung cancer. - Safusidenib: A mIDH1 inhibitor in Phase 2 clinical trials for IDH1-mutant Grades 2 and 3 glioma, cholangiocarcinoma, and other tumors. - Focus on developing therapies that target specific genetic mutations in tumors. </features> <target_audience> The primary target audience includes patients with ROS1-positive non-small cell lung cancer and IDH1-mutant gliomas and cholangiocarcinoma, as well as the oncologists and healthcare providers who treat them. </target_audience> ```

What does AnHeart Therapeutics do?

When was AnHeart Therapeutics founded?

AnHeart Therapeutics was founded in 2018.

How much funding has AnHeart Therapeutics raised?

AnHeart Therapeutics has raised 61000000.

Founded

2018

Funding

61000000

Employees

24 employees

Major Investors

Octagon Capital Advisors

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

AnHeart Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

anhearttherapeutics.com 3K+

Crunchbase

Founded 2018

Funding

Estimated Funding

$50M+

Major Investors

Octagon Capital Advisors

Team (20+)

No team information available.

Company Description

Problem

Many cancers are driven by specific genetic mutations, but traditional chemotherapy and radiation treatments lack the precision to target these mutations, leading to off-target effects and limited efficacy. This results in suboptimal patient outcomes and a need for therapies that selectively inhibit the growth of tumor cells harboring specific mutations.

Solution

AnHeart Therapeutics develops precision oncology therapeutics designed to target specific genetic mutations found in tumors. Their lead compounds, Taletrectinib and Safusidenib, are designed to selectively inhibit ROS1 and IDH1 mutations, respectively. By targeting these specific mutations, the company aims to improve treatment efficacy and patient outcomes while minimizing off-target effects. Both Taletrectinib and Safusidenib are currently in Phase 2 clinical trials for various cancers.

Features

Taletrectinib: A ROS1 inhibitor in Phase 2 clinical trials for ROS1-positive non-small cell lung cancer.

Safusidenib: A mIDH1 inhibitor in Phase 2 clinical trials for IDH1-mutant Grades 2 and 3 glioma, cholangiocarcinoma, and other tumors.

Focus on developing therapies that target specific genetic mutations in tumors.

Target Audience

The primary target audience includes patients with ROS1-positive non-small cell lung cancer and IDH1-mutant gliomas and cholangiocarcinoma, as well as the oncologists and healthcare providers who treat them.